Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
NCT04272151Phase 2Unknown
- Sponsor
- Chongqing Precision Biotech
- Start
- Dec 2019
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BCMA CAR-T cells in multiple myeloma (MM), sponsored by Chongqing Precision Biotech. Primary endpoints: Adverse events that related to treatment at 2 years and Response rate of BCMA CAR-T treatment at 6 months. Status: unknown.
02
Drugs
BCMA CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04272151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04272151.